Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"

Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst commented, "SRPT is a pot'l recovery story in 2026: (1) A new Elevidys launch initiative could enable sales to rebound in H2:26 (80% of ambulatory DMD pts are still untreated), (2) In Q1:26, we think initial DM1/FSHD data ($1B+ oppty apiece) could be informative, with more complete MAD data in H2:26 to be certainly conclusive (+25-50% stock move), (3) In Q1:26, mgmt believes an FDA meeting on the next steps for two PMOs (post ESSENSE data) should lead to a (+) outcome. "

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $16.32 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Bitmine Immersion Technologies plans $300 million preferred stock offering
• Greenway Technologies board member Raymond Wright resigns